Patient experience study after first treatment for advanced gynecologic cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at the experiences of people with advanced gynecologic cancers after they finish their first treatment and their disease is stable. It aims to understand their journey and quality of life, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with stage III or IV cervical cancer or endometrial (uterine) cancer.
- You completed your first round of standard treatment (chemotherapy, radiation, or both) within 6 months of diagnosis, between December 2022 and December 2024.
- Your doctor has told you that your cancer is stable (not growing or spreading).
- You have not had immunotherapy before and have not been in another clinical trial for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GV20-0251 combined with an immunotherapy (anti-PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial looks at what patients with advanced gynecologic cancer expect from care, and how well their care needs are being met. It uses questionnaires to learn what support is most helpful, especially near the end of life.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
This study follows young adults (ages 15-39) with gynecologic cancers to learn about their outcomes and improve care. By joining, you help researchers understand what treatments work best for people your age.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.